Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer.

Patients receiving sunitinib experienced significantly more dose delays (33.3% versus 8.7%, p =0.04), and had marginally lower mean RDI of doxorubicin/cyclophosphamide (92.2%±11.0% versus 96.7±6.4%, p =0.09), compared to those receiving chemotherapy alone (Table 2 ), although the difference did not reach statistical significance.

also in 111,027 other papers